These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

824 related items for PubMed ID: 27895131

  • 1. The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines.
    Espinosa DA, Vega-Rodriguez J, Flores-Garcia Y, Noe AR, Muñoz C, Coleman R, Bruck T, Haney K, Stevens A, Retallack D, Allen J, Vedvick TS, Fox CB, Reed SG, Howard RF, Salman AM, Janse CJ, Khan SM, Zavala F, Gutierrez GM.
    Infect Immun; 2017 Feb; 85(2):. PubMed ID: 27895131
    [Abstract] [Full Text] [Related]

  • 2. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
    Pirahmadi S, Zakeri S, A Mehrizi A, D Djadid N, Raz AA, J Sani J, Abbasi R, Ghorbanzadeh Z.
    Malar J; 2019 Apr 24; 18(1):146. PubMed ID: 31014347
    [Abstract] [Full Text] [Related]

  • 3. Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.
    Pirahmadi S, Zakeri S, Mehrizi AA, Djadid ND, Raz AA, Sani JJ.
    Infect Immun; 2019 Jun 24; 87(6):. PubMed ID: 30936155
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine.
    Alves E, Salman AM, Leoratti F, Lopez-Camacho C, Viveros-Sandoval ME, Lall A, El-Turabi A, Bachmann MF, Hill AV, Janse CJ, Khan SM, Reyes-Sandoval A.
    Clin Vaccine Immunol; 2017 Apr 24; 24(4):. PubMed ID: 28179403
    [Abstract] [Full Text] [Related]

  • 5. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R, DeBot M, Porter M, Nikki J, Rein L, Spaccapelo R, Crisanti A, Wightman PD, Ockenhouse CF, Dutta S.
    PLoS One; 2014 Apr 24; 9(10):e111020. PubMed ID: 25343487
    [Abstract] [Full Text] [Related]

  • 6. Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei.
    Bergmann-Leitner ES, Mease RM, De La Vega P, Savranskaya T, Polhemus M, Ockenhouse C, Angov E.
    PLoS One; 2010 Aug 19; 5(8):e12294. PubMed ID: 20808868
    [Abstract] [Full Text] [Related]

  • 7. Analysis of genetic diversity and population structure of gene encoding cell-traversal protein for ookinetes and sporozoites (CelTOS) vaccine candidate antigen in global Plasmodium falciparum populations.
    Pirahmadi S, Zakeri S, Mehrizi AA, Djadid ND.
    Infect Genet Evol; 2018 Apr 19; 59():113-125. PubMed ID: 29391203
    [Abstract] [Full Text] [Related]

  • 8. Heterogeneity in the acquisition of naturally acquired antibodies to cell-traversal protein for ookinetes and sporozoites (CelTOS) and thrombospondin-related adhesion protein (TRAP) of Plasmodium falciparum in naturally infected patients from unstable malaria areas in Iran.
    Pirahmadi S, Zakeri S, Mehrizi AA, Karimi L, Djadid ND.
    Acta Trop; 2019 Feb 19; 190():365-374. PubMed ID: 30543766
    [Abstract] [Full Text] [Related]

  • 9. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T, Komesu A, Otsuki H, Sattabongkot J, Udomsangpetch R, Matsumoto Y, Tsuji N, Wu Y, Torii M, Tsuboi T.
    Infect Immun; 2005 Nov 19; 73(11):7375-80. PubMed ID: 16239536
    [Abstract] [Full Text] [Related]

  • 10. Measuring naturally acquired ex vivo IFN-γ responses to Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (CelTOS) in Ghanaian adults.
    Anum D, Kusi KA, Ganeshan H, Hollingdale MR, Ofori MF, Koram KA, Gyan BA, Adu-Amankwah S, Badji E, Huang J, Belmonte M, Banania GJ, Kwofie TB, Villasante E, Dodoo D, Sedegah M.
    Malar J; 2015 Jan 21; 14():20. PubMed ID: 25604473
    [Abstract] [Full Text] [Related]

  • 11. Exploring in vitro expression and immune potency in mice using mRNA encoding the Plasmodium falciparum malaria antigen, CelTOS.
    Waghela IN, Mallory KL, Taylor JA, Schneider CG, Savransky T, Janse CJ, Lin PJC, Tam YK, Weissman D, Angov E.
    Front Immunol; 2022 Jan 21; 13():1026052. PubMed ID: 36591298
    [Abstract] [Full Text] [Related]

  • 12. Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS.
    Bergmann-Leitner ES, Legler PM, Savranskaya T, Ockenhouse CF, Angov E.
    Vaccine; 2011 Aug 11; 29(35):5940-9. PubMed ID: 21722682
    [Abstract] [Full Text] [Related]

  • 13. Malaria vaccine candidate antigen targeting the pre-erythrocytic stage of Plasmodium falciparum produced at high level in plants.
    Voepel N, Boes A, Edgue G, Beiss V, Kapelski S, Reimann A, Schillberg S, Pradel G, Fendel R, Scheuermayer M, Spiegel H, Fischer R.
    Biotechnol J; 2014 Nov 11; 9(11):1435-45. PubMed ID: 25200253
    [Abstract] [Full Text] [Related]

  • 14. Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.
    Longley RJ, Halbroth BR, Salman AM, Ewer KJ, Hodgson SH, Janse CJ, Khan SM, Hill AVS, Spencer AJ.
    Infect Immun; 2017 Mar 11; 85(3):. PubMed ID: 28031267
    [Abstract] [Full Text] [Related]

  • 15. Current Challenges in the Identification of Pre-Erythrocytic Malaria Vaccine Candidate Antigens.
    Bettencourt P.
    Front Immunol; 2020 Mar 11; 11():190. PubMed ID: 32153565
    [Abstract] [Full Text] [Related]

  • 16. An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens.
    Rodríguez-Galán A, Salman AM, Bowyer G, Collins KA, Longley RJ, Brod F, Ulaszewska M, Ewer KJ, Janse CJ, Khan SM, Hafalla JC, Hill AVS, Spencer AJ.
    Sci Rep; 2017 Dec 05; 7(1):17011. PubMed ID: 29209029
    [Abstract] [Full Text] [Related]

  • 17. Functional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate.
    Zheng W, Liu F, He Y, Liu Q, Humphreys GB, Tsuboi T, Fan Q, Luo E, Cao Y, Cui L.
    Parasit Vectors; 2017 Jan 05; 10(1):8. PubMed ID: 28057055
    [Abstract] [Full Text] [Related]

  • 18. Multistage protective anti-CelTOS monoclonal antibodies with cross-species sterile protection against malaria.
    Tang WK, Salinas ND, Kolli SK, Xu S, Urusova DV, Kumar H, Jimah JR, Subramani PA, Ogbondah MM, Barnes SJ, Adams JH, Tolia NH.
    Nat Commun; 2024 Aug 29; 15(1):7487. PubMed ID: 39209843
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM, Miura K, Sullivan J, Long CA, Barnwell JW.
    Malar J; 2016 Mar 15; 15():159. PubMed ID: 26975721
    [Abstract] [Full Text] [Related]

  • 20. Th1 immune response to Plasmodium falciparum recombinant thrombospondin-related adhesive protein (TRAP) antigen is enhanced by TLR3-specific adjuvant, poly(I:C) in BALB/c mice.
    Mehrizi AA, Ameri Torzani M, Zakeri S, Jafary Zadeh A, Babaeekhou L.
    Parasite Immunol; 2018 Jul 15; 40(7):e12538. PubMed ID: 29799636
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.